Download Files:
CL075
$95 – $950
Products Details
Product Description
– CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively[1][2][3].
Web ID
– HY-117066
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C13H13N3S
References
– [1]Lai CY, et, al. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7. Vaccine. 2014 Sep 29;32(43):5593-9.|[2]Spranger S, et, al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol. 2010 Jul 1;185(1):738-47.|[3]Maalej KM, et, al. TLR8, but not TLR7, induces the priming of the NADPH oxidase activation in human neutrophils. J Leukoc Biol. 2015 Jun;97(6):1081-7.
CAS Number
– 256922-53-9
Molecular Weight
– 243.33
Compound Purity
– 99.25
SMILES
– NC1=NC2=CC=CC=C2C(S3)=C1N=C3CCC
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– DMSO : 22 mg/mL (ultrasonic;warming)
Target
– Toll-like Receptor (TLR)
Isoform
– TLR8
Pathway
– Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
